Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor

Phase 3

Terminated

Conditions: Gastrointestinal Stromal Tumor

Interventions: Biological: Bevacizumab
Drug: Imatinib Mesylate
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study

First Posted Date: 2006-05-11

Last Posted Date: 2017-09-14

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 12

Registration Number: NCT00324987

Locations: 🇺🇸
Community Medical Hospital, Missoula, Montana, United States
🇺🇸
Saint Patrick Hospital - Community Hospital, Missoula, Montana, United States
🇺🇸
Sanford Bismarck Medical Center, Bismarck, North Dakota, United States

and more 189 locations

Polyunsaturated Fatty Acids (PUFA) in Diabetic Fatty Liver

Phase 2

Completed

Conditions: Fatty Liver

Interventions: Drug: Polyunsaturated fatty acid (Opti-EPA)
Drug: Placebo

First Posted Date: 2006-05-09

Last Posted Date: 2018-02-23

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 37

Registration Number: NCT00323414

Locations: 🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸
MetroHealth Medical Center, Cleveland, Ohio, United States

CDDO to Treat Solid Tumors and Lymphomas

Phase 1

Completed

Conditions: Solid Tumors
Lymphoma

First Posted Date: 2006-05-05

Last Posted Date: 2017-07-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 7

Registration Number: NCT00322140

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

AZD2171 to Treat Children and Adolescents With Solid Tumors or Acute Myelogenous Leukemia

Phase 1

Completed

Conditions: Refractory or Recurrent Solid Tumors
Acute Myelogenous Leukemia

First Posted Date: 2006-05-04

Last Posted Date: 2019-11-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 18

Registration Number: NCT00321581

Locations: 🇺🇸
Childrens Hospital, Philadelphia, Philadelphia, Pennsylvania, United States

Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery

Phase 1

Completed

Conditions: Adult Primary Hepatocellular Carcinoma
Advanced Adult Primary Liver Cancer
Localized Unresectable Adult Primary Liver Cancer
Recurrent Adult Primary Liver Cancer

Interventions: Drug: belinostat

First Posted Date: 2006-05-04

Last Posted Date: 2017-11-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 54

Registration Number: NCT00321594

Locations: 🇸🇬
Cancer Therapeutics Research Group, Singapore, Singapore
🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States

AZD2171 in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: B-cell Chronic Lymphocytic Leukemia
Refractory Chronic Lymphocytic Leukemia

Interventions: Drug: cediranib maleate
Other: laboratory biomarker analysis

First Posted Date: 2006-05-04

Last Posted Date: 2013-01-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 35

Registration Number: NCT00321724

Locations: 🇺🇸
North Central Cancer Treatment Group, Rochester, Minnesota, United States

LMB-2 to Treat Hairy Cell Leukemia

Phase 2

Completed

Conditions: Hairy Cell Leukemia

Interventions: Drug: Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin

First Posted Date: 2006-05-04

Last Posted Date: 2023-11-14

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 15

Registration Number: NCT00321555

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Bevacizumab, Radiation Therapy, and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Nonmetastatic Rectal Cancer

Phase 2

Completed

Conditions: Stage II Rectal Cancer AJCC v7
Stage III Rectal Cancer AJCC v7
Rectal Adenocarcinoma

Interventions: Biological: Bevacizumab
Drug: Capecitabine
Drug: Fluorouracil
Drug: Leucovorin Calcium
Drug: Oxaliplatin
Radiation: Radiation Therapy
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2006-05-04

Last Posted Date: 2019-03-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 57

Registration Number: NCT00321685

Locations: 🇺🇸
Einstein Medical Center Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Sparta Cancer Treatment Center, Sparta, New Jersey, United States
🇺🇸
Nebraska Cancer Research Center, Lincoln, Nebraska, United States

and more 104 locations

Budesonide in Treating Patients With Lung Nodules at High Risk of Developing Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Other: Placebo
Drug: Budesonide

First Posted Date: 2006-05-04

Last Posted Date: 2016-01-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 225

Registration Number: NCT00321893

Locations: 🇮🇹
European Institute of Oncology, Milan, Italy

Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Phase 1

Completed

Conditions: Adult Giant Cell Glioblastoma
Adult Glioblastoma
Adult Gliosarcoma

Interventions: Other: pharmacological study
Procedure: adjuvant therapy
Radiation: 3-dimensional conformal radiation therapy
Radiation: intensity-modulated radiation therapy
Drug: temsirolimus
Drug: temozolomide

First Posted Date: 2006-04-21

Last Posted Date: 2013-04-10

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 56

Registration Number: NCT00316849

Locations: 🇺🇸
Altru Cancer Center, Grand Forks, North Dakota, United States
🇺🇸
Medical Oncology and Hematology Associates, Des Moines, Iowa, United States
🇺🇸
Iowa Lutheran Hospital, Des Moines, Iowa, United States

and more 8 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy